While some patients and physicians are not aware of the costs of care, others are concerned about whether they can afford treatment options at all. Dr Miller describes some of the major steps to the incremental benefits and incremental costs incurred by new agents.
While some patients and physicians are not aware of the costs of care, others are concerned about whether they can afford treatment options at all. Dr Miller describes some of the major steps to the incremental benefits and incremental costs incurred by new agents.
“We’re recommending that actually, when these patients are screened and are positive, that they actually get appropriately staged by a hepatologist. This has become much more complex, and even though the agents are orally available now—which means many more primary care doctors may want to attempt to treat these patients—I think proper identification of which patients should be treated, and making sure that they’re really being worked up appropriately and tracked appropriately, is going to be crucial,” he says. “This is becoming a much more complex disease to treat. The great news is that it’s also becoming much more treatable. We’re recommending to our clients that they encourage evaluation by a hepatologist.”
Dr Wilson suggests that new agents add tremendous value, especially when compared to other treatments historically. The cost equation, however, can be overwhelming.
The panelists go on to discuss how sofosbuvir and simeprevir showed improvement in hard-to-treat patients, or those who failed to showed improvement with interferon-based treatment. Outcomes of these new treatments can be tremendous, but how these patients can receive treatment may be the real challenge.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More